AcelRx Pharmaceuticals, Inc. (ACRX): Price and Financial Metrics
GET POWR RATINGS... FREE!
ACRX POWR Grades
- ACRX scores best on the Value dimension, with a Value rank ahead of 85.12% of US stocks.
- ACRX's strongest trending metric is Stability; it's been moving down over the last 145 days.
- ACRX ranks lowest in Stability; there it ranks in the 1st percentile.
ACRX Stock Summary
- ACELRX PHARMACEUTICALS INC's market capitalization of $5,393,341 is ahead of just 1.96% of US-listed equities.
- ACRX's current price/earnings ratio is 0.11, which is higher than merely 0.04% of US stocks with positive earnings.
- Equity multiplier, or assets relative to shareholders' equity, comes in at -18.43 for ACELRX PHARMACEUTICALS INC; that's greater than it is for only 1.15% of US stocks.
- If you're looking for stocks that are quantitatively similar to ACELRX PHARMACEUTICALS INC, a group of peers worth examining would be LPTH, TALK, XGN, ANGO, and LIQT.
- Visit ACRX's SEC page to see the company's official filings. To visit the company's web site, go to www.acelrx.com.
ACRX Valuation Summary
- ACRX's price/sales ratio is 3.2; this is 31.91% lower than that of the median Healthcare stock.
- ACRX's price/sales ratio has moved NA NA over the prior 147 months.
Below are key valuation metrics over time for ACRX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ACRX | 2023-03-17 | 3.2 | 0.2 | 0.1 | 0.0 |
| ACRX | 2023-03-16 | 3.4 | 0.2 | 0.1 | 0.0 |
| ACRX | 2023-03-15 | 3.5 | 0.2 | 0.1 | 0.0 |
| ACRX | 2023-03-14 | 4.3 | 0.2 | 0.1 | 0.0 |
| ACRX | 2023-03-13 | 5.4 | 0.3 | 0.2 | 0.1 |
| ACRX | 2023-03-10 | 5.8 | 0.3 | 0.2 | 0.1 |
ACRX Growth Metrics
- Its 4 year net cashflow from operations growth rate is now at -70.37%.
- The 3 year net cashflow from operations growth rate now stands at 16.35%.
- The 4 year net income to common stockholders growth rate now stands at -16.27%.
The table below shows ACRX's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 1.521 | -30.922 | 47.136 |
| 2022-06-30 | 2.876 | -29.627 | 45.697 |
| 2022-03-31 | 2.749 | -29.228 | -34.817 |
| 2021-12-31 | 2.818 | -30.002 | -35.099 |
| 2021-09-30 | 3.554 | -28.325 | -36.1 |
| 2021-06-30 | 3.06 | -32.506 | -36.655 |
ACRX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ACRX has a Quality Grade of F, ranking ahead of 2.01% of graded US stocks.
- ACRX's asset turnover comes in at 0.041 -- ranking 335th of 680 Pharmaceutical Products stocks.
- JNJ, ORGS, and ABBV are the stocks whose asset turnover ratios are most correlated with ACRX.
The table below shows ACRX's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.041 | -0.709 | -0.606 |
| 2021-03-31 | 0.077 | -0.004 | -0.552 |
| 2020-12-31 | 0.078 | -0.114 | -0.640 |
| 2020-09-30 | 0.068 | -0.232 | -0.616 |
| 2020-06-30 | 0.052 | -0.513 | -0.580 |
| 2020-03-31 | 0.025 | -1.941 | -0.632 |
ACRX Price Target
For more insight on analysts targets of ACRX, see our ACRX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $6.00 | Average Broker Recommendation | 1.5 (Moderate Buy) |
ACRX Stock Price Chart Interactive Chart >
ACRX Price/Volume Stats
| Current price | $0.70 | 52-week high | $7.60 |
| Prev. close | $0.72 | 52-week low | $0.57 |
| Day low | $0.67 | Volume | 115,800 |
| Day high | $0.72 | Avg. volume | 226,837 |
| 50-day MA | $1.58 | Dividend yield | N/A |
| 200-day MA | $3.37 | Market Cap | 5.21M |
AcelRx Pharmaceuticals, Inc. (ACRX) Company Bio
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes therapies for the treatment of acute pain. The company was founded in 2005 and is based in Redwood City, California.
Latest ACRX News From Around the Web
Below are the latest news stories about ACELRX PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ACRX as an investment opportunity.
AcelRx to Host Full Year and Fourth Quarter 2022 Financial Results Call and Webcast on March 30, 2023AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release full year and fourth quarter financial results for 2022 after the market close on Thursday, March 30, 2023. Thereafter, AcelRx management will host a live webcast and conference call at 4:30 p.m. Eastern Daylight Time/1:30 p.m. Pacific Daylight Time on March 30, 2023 |
AcelRx Pharmaceuticals Announces Divestment of DSUVIA® to Alora PharmaceuticalsAcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the divestment of its FDA-approved drug, DSUVIA® to Alora Pharmaceuticals (Alora). The agreement allows AcelRx to participate in the long-term value expected to be created by Alora as they expand the commercialization of DSUVIA. |
AcelRx Pharmaceuticals Announces Peer-Reviewed Publication On the Use of DSUVIA® For In-Office Rhinology ProceduresAcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the publication of a report arising from a series of rhinology procedures successfully performed using sufentanil sublingual tablet 30 mcg (SST; DSUVIA) in Otolaryngology Case Reports. The study was lead-authored by otolaryngologist Dr. Ashley Sikand and entitled "Evaluation of |
AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Q3 2022 Earnings Call TranscriptAcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Q3 2022 Earnings Call Transcript November 14, 2022 AcelRx Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.94, expectations were $-1.2. Operator: Welcome to the AcelRx Third Quarter 2022 Earnings Call. This call is being webcast live via the Events page of the Investors section of AcelRx’s website at www.acelrx.com. This […] |
AcelRx Announces $7.5 Million Registered Direct Offering of Common Stock and Warrants to Purchase Common StockAcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced it has entered into an agreement with a life sciences-focused investment fund for the sale of 748,744 shares of its common stock, pre-funded warrants exercisable for an aggregate of 2,632,898 shares of common stock and common warrants exercisable for an aggregate of 4,227,052 sha |
ACRX Price Returns
| 1-mo | -51.39% |
| 3-mo | -66.18% |
| 6-mo | -83.11% |
| 1-year | -88.89% |
| 3-year | -97.18% |
| 5-year | -98.51% |
| YTD | -69.03% |
| 2022 | -79.83% |
| 2021 | -54.82% |
| 2020 | -41.23% |
| 2019 | -8.66% |
| 2018 | 14.07% |
Continue Researching ACRX
Want to see what other sources are saying about Acelrx Pharmaceuticals Inc's financials and stock price? Try the links below:Acelrx Pharmaceuticals Inc (ACRX) Stock Price | Nasdaq
Acelrx Pharmaceuticals Inc (ACRX) Stock Quote, History and News - Yahoo Finance
Acelrx Pharmaceuticals Inc (ACRX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...